Telix Pharmaceuticals Limited American Depositary Shares TLX
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $21.33 (+120.6% upside)
Key Stats
- Today's Range
- $9.67 – $9.87
- 50-Day Range
- $8.91 – $13.11
- 52-Week Range
- $6.28 – $13.11
- Volume
- 39K shs
- Average Volume
- 361K shs
- Market Cap
- $3.29 billion
- P/E Ratio
- —
- Dividend Yield
- 1.45%
Dividend
- Dividend Yield
- 1.45%
- Annual Dividend
- $0.14
- Payout Ratio
- —
- Ex-Dividend Date
- 2006-04-18
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Telix Pharmaceuticals Limited American Depositary Shares
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Related Stocks
Compare head-to-head: TLX vs AAPL·TLX vs NVDA·TLX vs MSFT·TLX vs GOOGL
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.